IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application Of: Shim, et al.

Group No.: TBD

Serial No.: 10/550,525
International Application No.: PCT/US04/09570

Docket No. 050508-1370

International Filing Date: March 26, 2004

For: **CXCR4 Antagonists and Methods of Their Use**

<u>STATEMENT REGARDING SEQUENCE LISTING COMPLYING WITH STANDARD</u>

Commissioner for Patents
Mail Stop Sequence Listing
PO Box 1450
Alexandria, VA 22313-1450

Sir:

The information recorded in computer readable form on the attached disk is identical to the written (on paper) sequence listing of the above-referenced application.

Respectfully submitted,

Christopher B. Linder; Reg. No. 47,751
Attorney for Applicant

**THOMAS, KAYDEN, HORSTEMEYER
& RISLEY, L.L.P.**
Suite 1750
100 Galleria Parkway, N.W.
Atlanta, GA 30339-5948
Telephone: (770) 933-9500
Facsimile: (770) 951-0933

<110> Emory University

<120> CXCR4 Antagonists and Methods of Their Use

<130> 50508-1370

<140> 2520406
<141> 2004-03-26

<160> 20

<170> PatentIn version 3.3

<210> 1
<211> 14
<212> PRT
<213> Artificial

<220>
<223> sequence of T140

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = Nal

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X = dLys

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> X = Cit

<400> 1

Arg Arg Xaa Cys Tyr Arg Lys Xaa Pro Tyr Arg Xaa Cys Arg
1   5   10

<210> 2
<211> 14
<212> PRT
<213> Artificial

<220>
<223> sequence of TN14003

<220>
<221> MISC_FEATURE
<222> (3)..(3)

<223>   X = Nal

<220>
<221>   MISC_FEATURE
<222>   (6)..(6)
<223>   X = Cit

<220>
<221>   MISC_FEATURE
<222>   (8)..(8)
<223>   X = dLys

<220>
<221>   MISC_FEATURE
<222>   (12)..(12)
<223>   X = Cit

<400>   2

Arg Arg Xaa Cys Tyr Xaa Lys Xaa Pro Tyr Arg Xaa Cys Arg
1   5   10

<210>   3
<211>   18
<212>   PRT
<213>   Artificial

<220>
<223>   sequence of T22

<400>   3

Arg Arg Trp Cys Tyr Arg Lys Cys Tyr Lys Gly Tyr Cys Tyr Arg Lys
1   5   10   15

Cys Arg

<210>   4
<211>   21
<212>   DNA
<213>   Artificial

<220>
<223>   cDNA sequence segments of CXCR4

<400>   4
aataaaatct tcctgcccac c   21

<210>   5
<211>   21
<212>   DNA
<213>   Artificial

```
<220>
<223>   cDNA sequence segments of CXCR4

<400>   5
aaggaagctg ttggctgaaa a                                          21


<210>   6
<211>   19
<212>   DNA
<213>   Artificial

<220>
<223>   CXCR4 cDNA target sequence

<400>   6
taactacacc gaggaaatg                                             19


<210>   7
<211>   19
<212>   DNA
<213>   Artificial

<220>
<223>   CXCR4 cDNA target sequence

<400>   7
tcttcttaac tggcattgt                                             19


<210>   8
<211>   19
<212>   DNA
<213>   Artificial

<220>
<223>   CXCR4 cDNA target sequences

<400>   8
tctttgccaa cgtcagtga                                             19


<210>   9
<211>   19
<212>   DNA
<213>   Artificial

<220>
<223>   CXCR4 cDNA target sequences

<400>   9
gtttcagcac atcatggtt                                             19


<210>   10
```

```
<211>  19
<212>  DNA
<213>  Artificial

<220>
<223>  CXCR4 cDNA target sequence

<400>  10
catcatggtt ggccttatc                                                    19


<210>  11
<211>  19
<212>  DNA
<213>  Artificial

<220>
<223>  CXCR4 cDNA target sequences

<400>  11
tcctgcctgg tattgtcat                                                    19


<210>  12
<211>  19
<212>  DNA
<213>  Artificial

<220>
<223>  CXCR4 cDNA target sequences

<400>  12
tcctgtcctg ctattgcat                                                    19


<210>  13
<211>  19
<212>  DNA
<213>  Artificial

<220>
<223>  CXCR4 cDNA target sequences

<400>  13
gcatcgactc cttcatcct                                                    19


<210>  14
<211>  19
<212>  DNA
<213>  Artificial

<220>
<223>  CXCR4 cDNA target sequences

<400>  14
ggaaagcgag gtggacatt                                                    19
```

```
<210>  15
<211>  25
<212>  DNA
<213>  Artificial

<220>
<223>  siRNA

<400>  15
aauaaaaucu uccugcccac cdtdt                                              25


<210>  16
<211>  25
<212>  DNA
<213>  Artificial

<220>
<223>  siRNA

<400>  16
aaggaagcug uuggcugaaa adtdt                                              25


<210>  17
<211>  20
<212>  DNA
<213>  Artificial

<220>
<223>  CXCR4-specific primers

<400>  17
gaaccctgtt tccgtgaaga                                                    20


<210>  18
<211>  20
<212>  DNA
<213>  Artificial

<220>
<223>  CXCR4-specific primers

<400>  18
cttgtccgtc atgcttctca                                                    20


<210>  19
<211>  20
<212>  DNA
<213>  Artificial

<220>
<223>  primer
```

```
<400>  19
gacaggatgc agaaggagat                                              20


<210>  20
<211>  20
<212>  DNA
<213>  Artificial

<220>
<223>  primer

<400>  20
tgcttgctga tccacatctg                                              20
```

SEQUENCE LISTING

<110>   Emory University

<120>   CXCR4 Antagonists and Methods of Their Use

<130>   50508-2331

<140>   2520406
<141>   2004-03-26

<160>   20

<170>   PatentIn version 3.3

<210>   1
<211>   14
<212>   PRT
<213>   Artificial

<220>
<223>   sequence of T140

<220>
<221>   MISC_FEATURE
<222>   (3)..(3)
<223>   X = Nal

<220>
<221>   MISC_FEATURE
<222>   (8)..(8)
<223>   X = dLys

<220>
<221>   MISC_FEATURE
<222>   (12)..(12)
<223>   X = Cit

<400>   1

Arg Arg Xaa Cys Tyr Arg Lys Xaa Pro Tyr Arg Xaa Cys Arg
1   5   10

<210>   2
<211>   14
<212>   PRT
<213>   Artificial

<220>
<223>   sequence of TN14003

<220>
<221>   MISC_FEATURE
<222>   (3)..(3)
<223>   X = Nal

<220>
<221>   MISC_FEATURE
<222>   (6)..(6)
<223>   X = Cit

```
<220>
<221>   MISC_FEATURE
<222>   (8)..(8)
<223>   X = dLys

<220>
<221>   MISC_FEATURE
<222>   (12)..(12)
<223>   X = Cit

<400>   2
```

Arg Arg Xaa Cys Tyr Xaa Lys Xaa Pro Tyr Arg Xaa Cys Arg
1   5   10

```
<210>   3
<211>   18
<212>   PRT
<213>   Artificial

<220>
<223>   sequence of T22

<400>   3
```

Arg Arg Trp Cys Tyr Arg Lys Cys Tyr Lys Gly Tyr Cys Tyr Arg Lys
1   5   10   15

Cys Arg

```
<210>   4
<211>   21
<212>   DNA
<213>   Artificial

<220>
<223>   cDNA sequence segments of CXCR4

<400>   4
aataaaatct tcctgcccac c                                          21

<210>   5
<211>   21
<212>   DNA
<213>   Artificial

<220>
<223>   cDNA sequence segments of CXCR4

<400>   5
aaggaagctg ttggctgaaa a                                          21

<210>   6
<211>   19
<212>   DNA
<213>   Artificial
```

```
<220>
<223>  CXCR4 cDNA target sequence

<400>  6
taactacacc gaggaaatg                                              19


<210>  7
<211>  19
<212>  DNA
<213>  Artificial

<220>
<223>  CXCR4 cDNA target sequence

<400>  7
tcttcttaac tggcattgt                                              19


<210>  8
<211>  19
<212>  DNA
<213>  Artificial

<220>
<223>  CXCR4 cDNA target sequences

<400>  8
tctttgccaa cgtcagtga                                              19


<210>  9
<211>  19
<212>  DNA
<213>  Artificial

<220>
<223>  CXCR4 cDNA target sequences

<400>  9
gtttcagcac atcatggtt                                              19


<210>  10
<211>  19
<212>  DNA
<213>  Artificial

<220>
<223>  CXCR4 cDNA target sequence

<400>  10
catcatggtt ggccttatc                                              19


<210>  11
<211>  19
<212>  DNA
<213>  Artificial

<220>
<223>  CXCR4 cDNA target sequences
```

<400> 11
tcctgcctgg tattgtcat   19

<210> 12
<211> 19
<212> DNA
<213> Artificial

<220>
<223> CXCR4 cDNA target sequences

<400> 12
tcctgtcctg ctattgcat   19

<210> 13
<211> 19
<212> DNA
<213> Artificial

<220>
<223> CXCR4 cDNA target sequences

<400> 13
gcatcgactc cttcatcct   19

<210> 14
<211> 19
<212> DNA
<213> Artificial

<220>
<223> CXCR4 cDNA target sequences

<400> 14
ggaaagcgag gtggacatt   19

<210> 15
<211> 25
<212> DNA
<213> Artificial

<220>
<223> siRNA

<400> 15
aauaaaaucu uccugcccac cdtdt   25

<210> 16
<211> 25
<212> DNA
<213> Artificial

<220>
<223> siRNA

<400> 16
aaggaagcug uuggcugaaa adtdt   25

```
<210>  17
<211>  20
<212>  DNA
<213>  Artificial

<220>
<223>  CXCR4-specific primers

<400>  17
gaaccctgtt tccgtgaaga                                              20


<210>  18
<211>  20
<212>  DNA
<213>  Artificial

<220>
<223>  CXCR4-specific primers

<400>  18
cttgtccgtc atgcttctca                                              20


<210>  19
<211>  20
<212>  DNA
<213>  Artificial

<220>
<223>  primer

<400>  19
gacaggatgc agaaggagat                                              20


<210>  20
<211>  20
<212>  DNA
<213>  Artificial

<220>
<223>  primer

<400>  20
tgcttgctga tccacatctg                                              20
```

IMATION

Revised Sequence Listing
10/520, 525

EXPRESS MAIL
UNITED STATES POSTAL SERVICE

EV 749201497 US

EXPRESS MAIL
UNITED STATES POSTAL SERVICE
www.usps

EXPRESS
MAIL
UNITED STATES POSTAL SERVICE
CORPORATE
POSTAGE AND FE

Mailing Label
Label 11-F. April 2004

Post Office To Addressee

ORIGIN (POSTAL SERVICE USE ONLY)

PO ZIP Code	Day of Delivery	Postage
	☐ Next ☐ 2nd ☐ 2nd Del. Day	$
Date Accepted	Scheduled Date of Delivery	Return Receipt Fee
	Month Day	$
Mo. Day Year	Scheduled Time of Delivery	COD Fee	Insurance Fee
Time Accepted ☐ AM ☐ PM	☐ Noon ☐ 3 PM	$	$
	Military	Total Postage & Fees
Flat Rate ☐ or Weight	☐ 2nd Day ☐ 3rd Day	$
____ lbs. ____ ozs.	Int'l Alpha Country Code	Acceptance Emp. Initials

CUSTOMER USE ONLY
METHOD OF PAYMENT:
Express Mail Corporate Acct. No.   X301897

FROM: (PLEASE PRINT)   PHONE (   )

THOMAS, KAYDEN, HORSTMEYER, &
RISLEY
100 GALLERIA PKWY SE STE 1750
ATLANTA   GA 30339-5961

050508-1370 (SAR/CAL)

DELIVERY (POSTAL USE ONLY)

Delivery Attempt	Time		Employee Signature
Mo. Day	☐ AM ☐ PM		
Delivery Attempt	Time		Employee Signature
Mo. Day	☐ AM ☐ PM		
Delivery Date	Time		Employee Signature
Mo. Day	☐ AM ☐ PM		

WAIVER OF SIGNATURE (Domestic Mail Only) Additional merchandise insurance is void if waiver of signature is requested...
☐ NO DELIVERY ☐ Weekend ☐ Holiday

Federal Agency Acct. No. or
Postal Service Acct. No.

TO: (PLEASE PRINT)   PHONE (   )

Commissioner for Patents
Mail Stop: PCT (DO/EO/US)
P.O. Box 1450
Alexandria, VA   22313-1450

PRESS HARD. YOU ARE MAKING 3 COPIES.

CALL 1-800-222-1811 FOR PICKUP OR TRACKING OF ALL YOUR PACKAGES

EXPRESS MAIL
UNITED STATES POSTAL SERVICE®
CORPORATE ACCOUNT
POSTAGE AND FEES PAID
Label 108
May 2000.

WWW.U...

EXPRESS MAIL
UNITED STATES POSTAL SERVICE®

EV 861590400 US

EXPRESS MAIL
UNITED STATES POSTAL SERVICE®

Mailing Label
Label 11-F. April 2004

Post Office To Addressee

@ USPS 1995

ORIGIN (POSTAL SERVICE USE ONLY)

PO ZIP Code	Day of Delivery	Postage
	☐ Next ☐ 2nd ☐ 2nd Del. Day	$
Date Accepted	Scheduled Date of Delivery	Return Receipt Fee
	Month Day	$
Mo. Day Year	Scheduled Time of Delivery	COD Fee / Insurance Fee
Time Accepted ☐ AM ☐ PM	☐ Noon ☐ 3 PM	$ / $
Flat Rate ☐ or Weight	Military ☐ 2nd Day ☐ 3rd Day	Total Postage & Fees
lbs. ozs.	Int'l Alpha Country Code	$
		Acceptance Emp. Initials

CUSTOMER USE ONLY
METHOD OF PAYMENT:
Express Mail Corporate Acct. No. X301897

FROM: (PLEASE PRINT)   PHONE (770) 933 9500

THOMAS, KAYDEN, HORSTMEYER, &
RISLEY
100 GALLERIA PKWY SE STE 1750
ATLANTA   GA 30339-5961

(SMICAL) 5058-1876

DELIVERY (POSTAL USE ONLY)

Delivery Attempt	Time	☐ AM ☐ PM	Employee Signature
Mo. Day			
Delivery Attempt	Time	☐ AM ☐ PM	Employee Signature
Mo. Day			
Delivery Date	Time	☐ AM ☐ PM	Employee Signature
Mo. Day			

WAIVER OF SIGNATURE (Domestic Mail Only) Additional merchandise insurance is void if waiver of signature is requested. I wish delivery to be made without obtaining signature of addressee or addressee's agent (if delivery employee judges that article can be left in secure location) and I authorize that delivery employee's signature constitutes valid proof of delivery.

NO DELIVERY ☐ Weekend ☐ Holiday   Customer Signature

Federal Agency Acct. No. or
Postal Service Acct. No.

TO: (PLEASE PRINT)   PHONE (   )

Mail Stop: PET (Doltolus)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FOR PICKUP OR TRACKING: Visit **www.usps.com** or Call 1-800-222-1811

367/ 500   F:02 T:

EMS

PRESS HARD. YOU ARE MAKING 3 COPIES.

IMATION

5D5D8 - 1370

Filed/Date Mailed: September 22, 2005
Applicant: Shim et al.
Docket #: **050508-1370**
Title: CXCR4 Antagonists and Methods of Their Use
EM #: EV628221771US

Due Date: September 27, 2005
PCT #: PCT/US2004/009570
Parent Applic.:

PATENT AND TRADEMARK OFFICE (RECEIVING OFFICE) STAMP
HEREON ACKNOWLEDGES RECEIPT OF THE BELOW IDENTIFIED APPLICATION AND PAPERS:

USPTO STAMP

10/550525

Fees:
Pymt
Form

- ☒ Express Cert. of Mailing
- ☒ Fees: $440.00
- ☐ Check
- ☐ Dep. Acct:
- ☐ Fee Calculation Sheet

- ☐ PCT/RO/101 (   ) Pages
- ☐ PCT Application Consisting of:
  - Pages of Specification
  - Pages of Claims
  - 1 Page of Abstract
  - Pages of Dwgs.
    - ☐ Formal ☐ Informal

- ☐ Article 19 Amendment Including:
- ☐ Article 34 Amendment Including
  - ☐ Explanation of Replac. Pgs.
  - ☐ Replacement Pages (   )
  - ☐ Other:

- ☐ Demand - Article 31 Including:
  - ☐ Demand for Chapter II
  - ☐ Copy of filed Art. 19/34 Amd.
  - ☐ Other:

- ☐ Response to Written Opinion
  - ☐ Explanation of Replac. Pgs.
  - ☐ Replacement Pages (   )

- ☐ General Appointment
- ☐ Pow. of Att. ☐ Orig. ☐ Copy

- ☐ Response to Invitation to Correct Defects Including:
  - ☐ Replacement Pages (   )
  - ☐ Specification (   )
  - ☐ Claims (   )
  - ☐ Abstract
  - ☐ Formal Drawings (   )
  - ☐ Identify Serial Number
    - ☐ 1st Prior. ☐ 2nd Prior.
  - ☐ Declaration/Power Attorney
    - ☐ Original ☐ Copy

- ☒ US Designated/Elected Office
  - ☒ 1st Subm. ☐ 2nd Subm.
  - ☐ Copy of Intern'l Application
  - ☐ Amend't to Claims (   )
  - ☐ Copy Int'l SX Report
  - ☐ Oath/Declaration
  - ☒ Other: PCT/IPEA/402; PCT/IB/301; Not. Re: Decl.

☒ Other: Copy of Sequence Listing Ver.; PCT Request; Credit Card Fm. ; _Preliminary Amendment; Seq. Listing Diskette_

Person Mailing: LLO

Responsible Atty: CBL

JC04 Rec'd PCT/PTO 22 SEP 2005